The Cardiovascular Effects of Neuropeptide Y (NPY)

Petty, Margaret A.; Dietrich, R.; Lang, R. E.

doi:10.3109/10641968409046098

Cited by 23 publications

(8 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They also demonstrate a dose-dependent reduction in myocardial contractility following intravenous NPY administration. The time course of the rise in MAP and of its subsequent recovery, is similar to that seen in the conscious rat (Petty et al 1984).…”

Section: Discussionsupporting

confidence: 70%

“…Most previous studies have attributed the bradycardia to baroreflex effects secondary to the increase in pressure (Lundberg & Tatemoto 1982;Petty et al 1984;Dahlof et al 1985;Corder et al 1986). In the current study in the conscious rabbit, the bradycardia following NPY injection persists after the pressor effect has disappeared, suggesting that the mechanism may be more complex than a purely reflex change mediated by the arterial baroreceptors.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of Neuropeptide Y on Left Ventricular Function in the Conscious Rabbit

Minson

McRitchie

Chalmers

1987

Clin Exp Pharma Physio

View full text Add to dashboard Cite

1. Changes in arterial pressure, heart rate and left ventricular contractility induced by intravenous injections of neuropeptide Y (NPY; 1-30 micrograms/kg) were studied in the conscious rabbit. 2. NPY has a brief pressor effect associated with a bradycardia, an increase in left ventricular end diastolic pressure, and a prolonged fall in peak left ventricular dP/dt (LVdP/dt). 3. The haemodynamic changes increase substantially with increasing doses up to 10 micrograms/kg. Beyond 10 micrograms/kg there are only slight effects on heart rate or peak LV dP/dt.

show abstract

Section: Discussionsupporting

confidence: 70%

Section: Discussionmentioning

confidence: 99%

Effects of Neuropeptide Y on Left Ventricular Function in the Conscious Rabbit

Minson

McRitchie

Chalmers

1987

Clin Exp Pharma Physio

View full text Add to dashboard Cite

show abstract

“…and peripheral administration, in both awake and anesthetized rats. In neither of these groups did NPY affect blood pressure or heart rate after central administration, but the previously known hypertensive effect of peripherally administered NPY was reliably reproduced (204). Microinjection of NPY into the posterior hypothalamus has been reported to produce a dose-related increase in the mean arterial blood pressure, possibly by histaminergic and/or cholinergic mechanisms (205).…”

Section: Central Blood Pressure Controlmentioning

confidence: 85%

Neuropeptide Y: an overview of central distribution, functional aspects, and possible involvement in neuropsychiatric illnesses

Heilig

Widerlöv

1990

Acta Psychiatr Scand

172

View full text Add to dashboard Cite

Neuropeptide Y (NPY) was first discovered and characterized as a 36-amino-acid peptide neurotransmitter in 1982. It is widely distributed in the central nervous system, with particularly high concentrations within several limbic and cortical regions. A number of co-localizations with other neuromessengers such as noradrenaline, somatostatin, and gamma-aminobutyric acid have been demonstrated. A large number of physiological and pharmacological actions of NPY have been suggested. Recent clinical data also suggest the involvement of NPY in several neuropsychiatric illnesses, particularly in depressive and anxiety states. This article gives a comprehensive review of central distribution of NPY and its receptors, co-localizations and interactions with other neuromessengers, genetic aspects, pharmacological and physiological actions, influence on neuroendocrine functions, and possible involvement in various neuropsychiatric illnesses.

show abstract

“…These results were obtained in vitro, in the absence of reflex activity which may result from the pressor, chronotropic or inotropic responses to drug infusion. Others have shown that the major part of the action of NPY in vivo is direct vasoconstriction and not the potentiation of other vasoconstrictors, such as NA (Lundberg et al, 1984b;Petty et al, 1984). In the rabbit isolated perfused heart, it has been shown that NPY had no effect on NAevoked changes in HR or dP/dt, indicating that NPY does not interact with noradrenergic transmission at its postsynaptic receptors .…”

Section: Discussionmentioning

confidence: 99%

The effects of neuropeptide Y on myocardial contractility and coronary blood flow

Awad

Einstein

Potter

et al. 1991

British J Pharmacology

View full text Add to dashboard Cite

1 This study was designed to assess the effects of exogenous neuropeptide Y (NPY) on cardiac contractility and coronary blood flow (CBF) in anaesthetized dogs and to evaluate the effect of NPY on the responses to sympathetic and parasympathetic stimulation and to inotropic agents.2 Bolus doses of NPY (500.ug), administered via the femoral vein, increased mean arterial pressure. The pressor effect was associated with reductions in heart rate, CBF and cardiac contractility. 3 The effects of NPY (500pug) on contractility and CBF were compared with that of vasopressin (VP) (1 unit). For similar reductions in CBF, NPY and VP had similar negative inotropic effects. Thus, it is likely that the negative inotropic response to NPY is not due to a direct effect of NPY on the heart muscle but is largely due to coronary vasoconstriction. 4 In the presence of NPY (500,pg, i.v.), there was an inhibition of the positive inotropic response to stimulation of the left cardiac sympathetic nerve (2 or 5Hz, 0.05 ms). NPY also inhibited the negative inotropic response and chronotropic response to vagal stimulation (2, 3 or 5 Hz, 0.05 ms). 5 Dose-response curves were obtained for the inotropic, chronotropic and pressor responses to cumulative infusions of noradrenaline (n = 6) and dobutamine (n = 6). NPY had no effect on these dose-response curves.6 The effect of NPY on the responses to salbutamol and impromidine was assessed. NPY did not alter the positive inotropic, chronotropic or depressor responses to these agonists. 7 Our results indicate that NPY has direct, postsynaptic vasoconstrictor activity and the reduction in myocardial contractility and heart rate are due to a combination of coronary vasoconstriction, baroreceptor reflex activation and presynaptic inhibition of transmitter release from sympathetic nerves. The welldocumented inhibitory effect of NPY on the chronotropic response to parasympathetic stimulation was confirmed and similar inhibition of the inotropic response to both sympathetic and parasympathetic stimulation was demonstrated. Since there was no modulation of the inotropic effects of exogenous a-and a1-adrenoceptor or H2-receptor agonists, it is concluded that the effects of NPY on myocardial contractility are exerted presynaptically.

show abstract

The Cardiovascular Effects of Neuropeptide Y (NPY)

Cited by 23 publications

References 7 publications

Effects of Neuropeptide Y on Left Ventricular Function in the Conscious Rabbit

Effects of Neuropeptide Y on Left Ventricular Function in the Conscious Rabbit

Neuropeptide Y: an overview of central distribution, functional aspects, and possible involvement in neuropsychiatric illnesses

The effects of neuropeptide Y on myocardial contractility and coronary blood flow

Contact Info

Product

Resources

About